BiotechTube

intravenous methylprednisolone

Pre-clinicalRecruiting
1 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuromyelitis Optica Spectrum Disorders

Conditions

Neuromyelitis Optica Spectrum Disorders

Trial Timeline

Apr 25, 2025 → Dec 31, 2026

NCT ID
NCT06763848

About intravenous methylprednisolone

intravenous methylprednisolone is a pre-clinical stage product being developed by Brain Biotech for Neuromyelitis Optica Spectrum Disorders. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06763848. Target conditions include Neuromyelitis Optica Spectrum Disorders.

What happened to similar drugs?

2 of 6 similar drugs in Neuromyelitis Optica Spectrum Disorders were approved

Approved (2) Terminated (1) Active (4)
✅Satralizumab 120 mgChugai PharmaceuticalApproved
✅InebilizumabAmgenApproved
🔄Satralizumab + Placebo + Baseline TreatmentChugai PharmaceuticalPhase 3
🔄Satralizumab + PlaceboChugai PharmaceuticalPhase 3
🔄satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroidsRochePhase 3
🔄SatralizumabRochePhase 3

Hype Score Breakdown

Clinical
3
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06763848Pre-clinicalRecruiting

Competing Products

8 competing products in Neuromyelitis Optica Spectrum Disorders

See all competitors
ProductCompanyStageHype Score
Satralizumab 120 mgChugai PharmaceuticalApproved
35
Satralizumab + Placebo + Baseline TreatmentChugai PharmaceuticalPhase 3
40
Satralizumab + PlaceboChugai PharmaceuticalPhase 3
40
satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroidsRochePhase 3
40
SatralizumabRochePhase 3
47
UPLIZNAAmgenPre-clinical
33
InebilizumabAmgenPhase 2
42
InebilizumabAmgenApproved
47